Multicentric Single Arm Phase II Clinical Trial, to Evaluate Safety and Efficacy of the Combination of Olaparib and PLD for Platinum Resistant Ovarian Primary Peritoneal Carcinoma, and Fallopian Tube Cancer Patients.
Phase of Trial: Phase II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Olaparib (Primary) ; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ROLANDO
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 26 Jan 2018 Status changed from not yet recruiting to recruiting.
- 14 Nov 2017 Planned End Date changed from 1 Feb 2020 to 1 Jun 2020.